Bone densitometry firm Lunar reported sharply higher revenueslast week for its first quarter (end-September). The Madison,WI, company had sales of $12.4 million, up 36% compared to revenuesof $9.1 million in the same period last year. The company's net
Bone densitometry firm Lunar reported sharply higher revenueslast week for its first quarter (end-September). The Madison,WI, company had sales of $12.4 million, up 36% compared to revenuesof $9.1 million in the same period last year.
The company's net income took a hit due to the costs of litigationwith competitor Hologic, however. Lunar's net profit was $1.3million, down 15% compared to net income of $1.6 million in lastyear's first quarter. Lunar spent $773,000 in the quarter on legalcosts related to the litigation, which was settled last month(SCAN 10/11/95).
The strong revenue growth was due to increased sales of Lunar'sExpert and DPX x-ray bone densitometers, as well as sales of theArtoscan MRI scanner, according to president Dr. Richard Mazess.Lunar expects increased Expert shipments in upcoming quartersas component shortages ease and as U.S. physicians begin prescribingMerck's new Fosamax drug for treating osteoporosis.
Lunar's stock enjoyed a boost last week on news that Merck'slicensing agreement with competitor CompuMed might not be as lucrativefor CompuMed as was initially thought (SCAN 9/13/95). CompuMed'sstock dropped almost 50% when the company disclosed that the agreementincluded a royalty cap in the last two years of the contract.Shares of Lunar stock jumped 8% to $37 a share shortly after therevelation.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.